Inflammatory Effect Articles & Analysis
16 news found
Unfortunately, these therapies do little to address the underlying inflammatory mechanisms that drive PAH or significantly improve survival rates. ...
Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. ...
Essential oils, derived from plants, offer a plethora of benefits, including aromatherapy, anti-inflammatory properties, and antibacterial effects. From soothing lavender and invigorating peppermint to calming chamomile, the company’s portfolio ensures that formulators have access to high-quality, pure essential oils that can elevate any skincare product. ...
Anti-LILRB2 mAb ES009 has demonstrated superior effects in converting immunosuppressive myeloid cells into pro-inflammation phenotypes in in vitro and ex vivo models. Highlights: ES009 specifically binds human LILRB2 with high affinity ES009 binds to a unique epitope on D1 domain of LILRB2 ES009 potently blocks LILRB2 binding to multiple ligands ES009 promotes monocytes ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors ...
In the treatment of DED, PDSPs are known to activate the proliferation and differentiation of limbal stem cells which leads to rapid repair of the cornea. They also have anti-inflammatory effects and can maintain the function of goblet cells and meibomian glands to improve tear quality in the long term. ...
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening ...
Invizius will use the financing to complete a First-in-Man safety study in 2022 of its H-Guard® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis. There are currently 3.3 million haemodialysis patients worldwide who receive treatment multiple times a week. ...
Bilirubin, a component extracted from pig blood, is a substance that has a strong antioxidant effect that removes active oxygen, and is known to have immune system regulating and anti-inflammatory effects. ...
Study results are expected towards the end of 2021 and will provide the basis for future clinical trials both in systemic sclerosis and potentially other chronic inflammatory diseases. Systemic sclerosis is a progressive, autoimmune disease that leads to serious damage to the microvasculature. ...
B244 was very well tolerated and side effects of the active were equal to that of the placebo. This was consistent with all previous trials the company has completed with this drug. ...
B244 was very well tolerated and side effects of the active were equal to that of the placebo. This was consistent with all previous trials the company has completed with this drug. ...
GS-248 is a potent and selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) and preclinical studies have demonstrated that inhibition of mPGES-1 provides a combination of anti-inflammatory, vasodilatory and platelet inhibitory effects. The Phase I study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ...
GS-248 is a potent and selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) in development for the treatment of microvascular diseases in chronic inflammatory conditions. Preclinical studies demonstrate that inhibition of mPGES-1 provides a combination of anti-inflammatory, vasodilatory and platelet inhibitory effects. ...
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, administered before and after primary hip or knee arthroplasty, to provide key insights into the immunomodulatory ...